MannKind Posts $23.2M Q3 Loss, Widening From $16.6M in Q1
MNKD sits 69% above its 52-week low of $2.23.
Summary
MannKind reported a $23.2 million net loss for the third quarter, a wider loss than the $16.6 million it posted in Q1 2026, on third-quarter revenue of $101.9 million. That revenue is below the $109.4 million posted in Q2, when revenue rose 43% year-over-year. The widening loss matters for a company of this size because it raises questions about cash burn and how much of the recent revenue ramp is being consumed by operating costs. The Q2 report in August was the last major fundamental update; this is the first hard number on Q3 profitability.
At the time of this announcement, MNKD was trading at $3.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.23 to $6.51. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.